株探米国株
英語
エドガーで原本を確認する
6-K 1 drr0494_6k.htm FORM 6-K

 

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

July, 2023

 

Commission File Number 1-15182

 

DR. REDDY’S LABORATORIES LIMITED

(Translation of registrant’s name into English)

 

8-2-337, Road No. 3, Banjara Hills

Hyderabad, Telangana 500 034, India

+91-40-49002900

 

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F  x  Form 40-F ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______

 

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

 

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

 

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes  ¨ No x

 

If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.

 

 

 

     

 

EXHIBITS

 

Exhibit Number   Description of Exhibits
     
99.1   Intimation dated July 15, 2023 titled Intimation of Security Subscription and Shareholders’ Agreement executed by Dr. Reddy’s Laboratories Limited with TEQ Green Power XI Private Limited and its affiliates

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  DR. REDDY’S LABORATORIES LIMITED (Registrant)
       
Date: July 15, 2023 By: /s/ K Randhir Singh
    Name: K Randhir Singh
    Title: Company Secretary

 

     

 

 

EX-99.1 2 drr0494_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

Dr. Reddy’s Laboratories Ltd.

8-2-337, Road No. 3, Banjara Hills,

Hyderabad - 500 034, Telangana,
India.

CIN : L85195TG1984PLC004507  

 

Tel      : +91 40 4900 2900

Fax     : +91 40 4900 2999

Email : mail@drreddys.com

www.drreddys.com

 

July 15, 2023

 

National Stock Exchange of India Ltd. (Stock Code: DRREDDY-EQ)

BSE Limited (Stock Code: 500124)

New York Stock Exchange Inc. (Stock Code: RDY)

NSE IFSC Ltd. (Stock Code: DRREDDY)

 

Dear Sirs,

 

Sub: Intimation of Security Subscription and Shareholders’ Agreement executed by Dr. Reddy’s Laboratories Limited with TEQ Green Power XI Private Limited and its affiliates

 

Ref: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

 

With reference to the captioned subject and in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the “SEBI Listing Regulations”), we hereby inform that Dr. Reddy’s Laboratories Limited (the “Company”) has entered into a Security Subscription and Shareholders’ Agreement for consumption and supply of renewable energy, with TEQ Green Power XI Private Limited and O2 Power SG Pte Ltd, for investment in O2 Renewable Energy IX Private Limited (“SPV”).

 

The disclosure required under Regulation 30 of the SEBI Listing Regulations read with Circular dated September 9, 2015, bearing reference no. CIR/CFD/CMD/4/2015 is enclosed herewith as Annexure-A.

 

Kindly take the above on your record.

 

Thanking you.

Yours faithfully,

For Dr. Reddy’s Laboratories Limited

 

/s/ K Randhir Singh  
K Randhir Singh  
Company Secretary, Compliance Officer and Head-CSR

 

Encl.: as above

 

     

 

 

Dr. Reddy’s Laboratories Ltd.

8-2-337, Road No. 3, Banjara Hills,

Hyderabad - 500 034, Telangana,
India.

CIN : L85195TG1984PLC004507  

 

Tel      : +91 40 4900 2900

Fax     : +91 40 4900 2999

Email : mail@drreddys.com

www.drreddys.com

 

Annexure A

 

S. No. Particulars Details
1. Name(s) of parties with whom the agreement is entered

O2 Renewable Energy IX Private Ltd (“SPV”);

TEQ Green Power XI Private Limited;

O2 Power SG Pte Ltd

2. Purpose of entering into the agreement For accessing renewable power through solar and wind power plants through (Inter-State Transmission System) ISTS under captive structure.
3. Shareholding, if any, in the entity with whom the agreement is executed Presently, the Company is not holding any shares in the proposed SPV.
4.

Significant terms of the agreement (in brief) special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc.

 

a)     The arrangement for accessing such renewable power will be done through a partnership with TEQ Green Power XI Private Limited and/or its affiliate with security holding ratio of 26% by the Company and 74% by TEQ Green Power XI Private Limited and/or its affiliate, in the SPV.

b)    The Company has the right to nominate 1(one) Director on the Board of SPV, receive first offer in case of transfer of securities of SPV to any third party, right to restrict capital restructuring, except otherwise defined, etc.

5. Whether,the said parties are related to promoter/promoter group/ group companies in any manner. If yes, nature of relationship No
6. Whether the transaction would fall within related party transactions? If yes, whether the same is done at “arms length”;

No

7. In case of issuance of shares to the parties, details of issue price, class of shares issued; The Company and TEQ Green Power XI Private Limited and/or its affiliate will invest in SPV in the ratio of  26:74.
8.

Any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising

out of such agreements, etc

As per para 4 above